Get started
Author

Catharine S. Leahy

Observed name: Catharine Leahy
OpenAlex ID: A5000285457
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
2018 · Dennis Dobrovolsky, Eric S. Wang, et al. · Blood · 166
PDF
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation
2023 · Matthew L. Arwood, Yao Liu, et al. · Cell chemical biology · 16
PDF
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence
2023 · Gongwei Wu, Noriaki Yoshida, et al. · Science Translational Medicine · 15
PDF
Mutation and cell state compatibility is required and targetable in Ph + acute lymphoblastic leukemia minimal residual disease
2024 · Peter S. Winter, Michelle L. Ramseier, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2
2022 · Gongwei Wu, Noriaki Yoshida, et al. · Blood · 2
Abstract 5755: TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2
2023 · Gongwei Wu, Noriaki Yoshida, et al. · Cancer Research
Abstract IA20: Aberrant leukemic developmental hierarchies and MRD-specific targeting informed by single-cell biophysical and molecular profiling
2020 · Peter S. Winter, Andrew Navia, et al. · Cancer Research
Abstract 2450: Single-cell profiling reveals programs mediating oncogenic kinase-independence and minimal residual disease in BCR-ABL-rearranged acute lymphoblastic leukemia
2019 · Mark A. Murakami, Peter S. Winter, et al. · Bioinformatics, Convergence Science, and Systems Biology
Abstract 2450: Single-cell profiling reveals programs mediating oncogenic kinase-independence and minimal residual disease in BCR-ABL-rearranged acute lymphoblastic leukemia
2019 · Mark A. Murakami, Peter S. Winter, et al. · Cancer Research
Development of a Reductive Photoredox System Using Riboflavin Analogues and Tris(bipyridine)ruthenium(II) Chloride
2018 · Catharine Leahy
Works count: 10
Citation count: 202
H-index: 3
I10-index: 3
Year
Topic
Type